IN2015DN01361A - - Google Patents
Info
- Publication number
- IN2015DN01361A IN2015DN01361A IN1361DEN2015A IN2015DN01361A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A IN 1361DEN2015 A IN1361DEN2015 A IN 1361DEN2015A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- fusion proteins
- constant regions
- incorporating
- igg
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 230000009870 specific binding Effects 0.000 abstract 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 1
- 101710120037 Toxin CcdB Proteins 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000014207 opsonization Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679045P | 2012-08-02 | 2012-08-02 | |
| US201361767724P | 2013-02-21 | 2013-02-21 | |
| PCT/US2013/053086 WO2014022592A1 (en) | 2012-08-02 | 2013-07-31 | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01361A true IN2015DN01361A (enrdf_load_stackoverflow) | 2015-07-03 |
Family
ID=50025683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1361DEN2015 IN2015DN01361A (enrdf_load_stackoverflow) | 2012-08-02 | 2013-07-31 |
Country Status (7)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741446B2 (en) | 2006-08-18 | 2010-06-22 | Armagen Technologies, Inc. | Fusion antibodies that cross the blood-brain barrier in both directions |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2013170168A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla Llc | Multi-specific monoclonal antibodies |
| US9540442B2 (en) | 2012-08-02 | 2017-01-10 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| WO2015132364A1 (en) * | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
| AU2015226101B2 (en) * | 2014-03-05 | 2019-08-22 | Ucb Biopharma Sprl | Multimeric Fc proteins |
| SG10201909716RA (en) | 2014-04-03 | 2019-11-28 | Igm Biosciences Inc | Modified j-chain |
| TW202132337A (zh) | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP6709456B2 (ja) * | 2014-12-19 | 2020-06-17 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | インターロイキン１５タンパク複合体およびそれらの用途 |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CA2972990A1 (en) | 2015-01-20 | 2016-07-28 | Beatrice Tien-Yi WANG | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| EP3957738A1 (en) * | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| CN107921285B (zh) | 2015-03-25 | 2022-06-07 | Igm生物科学股份有限公司 | 多价乙型肝炎病毒抗原结合分子及其应用 |
| KR20180002653A (ko) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
| HK1245675A1 (zh) | 2015-04-17 | 2018-08-31 | Igm Biosciences, Inc. | 多价人免疫缺陷病毒抗原结合分子及其用途 |
| TWI820377B (zh) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | 抗ｏｘ４０抗體及其使用方法 |
| WO2017059380A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
| DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| ES3026760T3 (en) | 2015-10-30 | 2025-06-12 | Galaxy Biotech Llc | Highly potent antibodies binding to death receptor 4 and death receptor 5 |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| US20170216452A1 (en) * | 2015-11-30 | 2017-08-03 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
| AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
| IL298686A (en) * | 2016-01-11 | 2023-01-01 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2018017761A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| WO2018017763A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| AU2017359467A1 (en) | 2016-11-09 | 2019-05-02 | Agenus Inc. | Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| US20210246227A1 (en) | 2017-05-31 | 2021-08-12 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| KR102232659B1 (ko) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도 |
| AU2019321490B2 (en) | 2018-08-13 | 2025-09-04 | Inhibrx Biosciences, Inc. | Ox40-binding polypeptides and uses thereof |
| JP7691365B2 (ja) * | 2018-12-27 | 2025-06-11 | エランコ・ユーエス・インコーポレイテッド | 動物用ＩｇＧＦｃバリアント |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN114127113A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与钙网蛋白结合的多功能分子及其用途 |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CN116249718A (zh) | 2020-08-26 | 2023-06-09 | 马伦戈治疗公司 | 结合至钙网蛋白的多功能性分子及其用途 |
| KR20230074487A (ko) | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
| KR20220029343A (ko) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물 |
| KR20220029524A (ko) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물 |
| JP2024515591A (ja) | 2021-04-08 | 2024-04-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｃｒに結合する多機能性分子およびその使用 |
| AU2022266780A1 (en) * | 2021-04-28 | 2023-11-09 | Ngm Biopharmaceuticals, Inc. | Multimerization of binding molecules having an antibody constant region variant |
| CN115724985A (zh) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | 一种cdc平台抗体 |
| GB202319645D0 (en) * | 2023-12-20 | 2024-01-31 | Kbio Holdings Ltd | Hexameric protein |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147326A1 (en) * | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| US6475749B1 (en) * | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| WO2008032833A1 (fr) * | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Anticorps présentant une activité adcc accrue et son procédé de production |
| GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| US8952134B2 (en) * | 2011-09-26 | 2015-02-10 | Jn Biosciences Llc | Hybrid constant regions |
| US9540442B2 (en) | 2012-08-02 | 2017-01-10 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
-
2013
- 2013-07-31 US US13/956,121 patent/US9540442B2/en active Active
- 2013-07-31 CN CN201380041074.3A patent/CN104684928A/zh active Pending
- 2013-07-31 EP EP13825409.9A patent/EP2880057A4/en not_active Withdrawn
- 2013-07-31 WO PCT/US2013/053086 patent/WO2014022592A1/en active Application Filing
- 2013-07-31 CA CA2879814A patent/CA2879814A1/en active Pending
- 2013-07-31 JP JP2015525568A patent/JP2015524821A/ja not_active Withdrawn
- 2013-07-31 IN IN1361DEN2015 patent/IN2015DN01361A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2880057A4 (en) | 2016-03-23 |
| US9540442B2 (en) | 2017-01-10 |
| CA2879814A1 (en) | 2014-02-06 |
| EP2880057A1 (en) | 2015-06-10 |
| CN104684928A (zh) | 2015-06-03 |
| JP2015524821A (ja) | 2015-08-27 |
| US20140037621A1 (en) | 2014-02-06 |
| WO2014022592A1 (en) | 2014-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01361A (enrdf_load_stackoverflow) | ||
| WO2009081285A3 (en) | Hepatitis c virus antibodies | |
| CA2849765C (en) | Hybrid constant regions | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| MX386942B (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| CY1120412T1 (el) | Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31 | |
| NZ706232A (en) | Anti-cd3 antibodies and uses thereof | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
| IN2014MN00873A (enrdf_load_stackoverflow) | ||
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| NZ600262A (en) | Anti-her3 antibodies and uses thereof | |
| DK2681244T3 (da) | Cea-antistoffer | |
| NZ578844A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
| NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ591056A (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| GB201005064D0 (en) | Biological products | |
| UY32752A (es) | Polipéptidos y Métodos de Tratamiento |